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Introduction: Diffuse alveolar damage (DAD) is the pathological hallmark of acute respiratory distress syndrome
(ARDS), however, the presence of DAD in the clinical criteria of ARDS patients by Berlin definition is little known.
This study is designed to investigate the role of DAD in ARDS patients who underwent open lung biopsy.
Methods: We retrospectively reviewed all ARDS patients who met the Berlin definition and underwent open lung
biopsy from January 1999 to January 2014 in a referred medical center. DAD is characterized by hyaline membrane
formation, lung edema, inflammation, hemorrhage and alveolar epithelial cell injury. Clinical data including baseline
characteristics, severity of ARDS, clinical and pathological diagnoses, and survival outcomes were analyzed.
Results: A total of 1838 patients with ARDS were identified and open lung biopsies were performed on 101
patients (5.5 %) during the study period. Of these 101 patients, the severity of ARDS on diagnosis was mild of
16.8 %, moderate of 56.5 % and severe of 26.7 %. The hospital mortality rate was not significant difference between
the three groups (64.7 % vs 61.4 % vs 55.6 %, p = 0.81). Of the 101 clinical ARDS patients with open lung biopsies,
56.4 % (57/101) patients had DAD according to biopsy results. The proportion of DAD were 76.5 % (13/17) in mild,
56.1 % (32/57) in moderate and 44.4 % (12/27) in severe ARDS and there is no significant difference between the
three groups (p = 0.113). Pathological findings of DAD patients had a higher hospital mortality rate than non-DAD
patients (71.9 % vs 45.5 %, p = 0.007). Pathological findings of DAD (odds ratio: 3.554, 95 % CI, 1.385–9.12; p = 0.008)
and Sequential Organ Failure Assessment score on the biopsy day (odds ratio: 1.424, 95 % CI, 1.187–1.707; p<0.001)
were significantly and independently associated with hospital mortality. The baseline demographics and clinical
characteristics were not significantly different between DAD and non-DAD patients.
Conclusions: The correlation of pathological findings of DAD and ARDS diagnosed by Berlin definition is modest.
A pathological finding of DAD in ARDS patients is associated with hospital mortality and there are no clinical
characteristics that could identify DAD patients before open lung biopsy.* Correspondence: kck0502@cgmh.org.tw
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In 1994 the American-European Consensus Conference
(AECC) released its definitions of acute lung injury
(ALI) and acute respiratory distress syndrome (ARDS)
[1]. Several studies had challenged the AECC criteria for
the diagnosis of ARDS because of its many limitations
[2–7]. To provide a more reliable definition of ARDS, an
expert panel revisited the AECC definition and released
the Berlin definition of ARDS [8]. However, the patho-
logical diagnosis of ARDS using lung biopsy was not in-
cluded in the Berlin definition because of the controversial
definition of the pathology and concern about surgical
complications [9].
It is essential to clarify the diagnosis of ARDS and to
initiate effective treatments such as low tidal volume and
prone positioning to improve clinical outcome [10–12].
The current clinical definition of ARDS reflects only
nonspecific functional or physiological abnormalities
rather than pathological abnormality. Since ARDS may
occur with other pathologic findings, it is uncertain if the
same management should be applied to all patients.
The heterogeneity of patients with ARDS included in
therapeutic trials remains a challenge when interpreting
results from such trials [13]. Therefore, open lung biopsy
sometimes has been performed to better define the
pathology and to guide therapeutic management of
selected patients with ARDS [14–17].
ARDS is a form of ALI characterized by severe inflam-
mation with increasing epithelial and endothelial perme-
ability [18]. The pathologic hallmark of ARDS is diffuse
alveolar damage (DAD) characterized by hyaline mem-
brane formation, lung edema, inflammation, hemorrhage
and alveolar epithelial cell injury [19, 20]. A post mortem
study showed that 66 % of 127 patients who met the
AECC definition of ARDS had typical DAD findings [21].
Another study reported that of the 64 patients diagnosed
as having ARDS using AECC criteria, 50 % (32/64) had
DAD findings at autopsy [22]. A large retrospective study
in Spain revealed that among 356 patients who met
the Berlin definition of ARDS, 45 % had DAD at autopsy
[23, 24]. However, autopsy results are based on results of
analysis of samples from deceased patients and thus, there
might be differences to results of analysis in the living.
The purpose of this study was to investigate the role
of DAD in patients with ARDS defined by the Berlin
definition on open lung biopsy.
Methods
Patient population
Our study was approved by the Institutional Review
Board of Chang Gung Memorial Hospital which waived
the need for informed consent due to the retrospective
nature of the study. Chang Gung Memorial Hospital is a
tertiary care referral center with a 3700-bed general ward,and a 278-bed adult ICU. The hospital charts of all patients
with ARDS who underwent open lung biopsy from January
1999 to January 2014 were reviewed. All patients who were
given a discharge diagnosis code of 518.82 (according to
the International Classification of Diseases, Ninth Revision,
Clinical Modification) were reviewed for possible inclusion
in this study.
Using the Berlin definition, ARDS was characterized as
mild if the arterial partial pressure of oxygen/inspired
oxygen fraction (PaO2/FiO2) was between 201 and 300
mm Hg, moderate if PaO2/FiO2 was between 101 and
200 mm Hg, and severe if PaO2/FiO2 was less than or
equal to 100 mm Hg, in all cases using either continuous
positive airway pressure (CPAP) or positive end-expiratory
pressure (PEEP) of at least 5 cm H2O [8]. A total of 1,838
patients with ARDS were identified by the chart sheets
and open lung biopsies were performed on 101 patients
(5.5 %). Those patients with a PaO2/FiO2 <200 while on
CPAP, or those treated with another noninvasive ven-
tilation approach classified as as having moderate or
severe ARDS were excluded. The ARDS severity was
characterized at the time of diagnosis. These 101 patients
included patients previously identified using the AECC
definition of ARDS, but reanalyzed in this study according
to the Berlin definition of ARDS [16, 25].
Microbiological examinations before open lung biopsy
The results of cultures from blood, sputum, transtracheal
aspiration, and pleural effusion were recorded. The location
for bronchoalveolar lavage (BAL) sampling was decided on
the basis of findings from high-resolution computed tomog-
raphy (HRCT) of the chest or chest x-ray (CXR), if HRCT
was not available. Each specimen was examined for
bacteria including Legionella, Mycoplasma pneumoniae,
Pneumocystis jiroveci, and Mycobacteria, and for fungi
and viruses (including cytomegalovirus, influenza virus,
parainfluenza virus, adenovirus, herpes simplex virus,
respiratory syncytial virus, and coxsackie virus). Specimens
were also sent for cytology and iron stain analysis. BAL
results were deemed positive when at the minimum one
microorganism had grown to a concentration greater than
104 colony-forming units/mL. All specimen examinations
were performed within 24 hours of open lung biopsy.
Open lung biopsy
Open lung biopsy was indicated when ARDS was
suspected to be noninfectious, there was no obvious
risk factor, and if there was a possible indication for
corticosteroid therapy based on clinical presentation
with rapid progression, relative symmetric distribution of
infiltrates on CXR, and predominant ground-glass
attenuation on HRCT of the chest. Informed consent for
surgical lung biopsy was obtained from each patient’s
family before surgery.
Kao et al. Critical Care  (2015) 19:228 Page 3 of 10Open lung biopsy was performed in an operating room
or at the bedside in the ICU. The lobe of the lung biopsy
was chosen based on the presence of a new or progressive
lesion identified on HRCT of the chest or CXR. While
under general anesthesia, open lung biopsy was performed
using either video-assisted thoracoscopic surgery (VATS)
or a 5-cm thoracotomy, depending on the patient’s
tolerance. For VATS and thoracotomy, an endoscopic
stapler-cutter was used to secure the pulmonary margins.
To avoid the risk of transfer to the operating room,
the timing of bedside open lung biopsy was considered
when the given FiO2 reached 1 with a PEEP above 12 cm
H2O. Each tissue specimen was cultured and examined by
pathologists.
Evaluation of pathological appearances
Pathological criteria for the diagnosis of pneumonia in-
volved severe neutrophil infiltration in the interstitium
and intra-alveolar spaces, particularly around terminal
bronchioles. The pathological criteria for the diagnosis
of ALI and DAD included the presence of pulmonary
inflammatory infiltrates and presence of hyaline mem-
brane formation and at least one of the following:
intra-alveolar edema, alveolar type I cell necrosis, alveolar
type II cell proliferation progressively covering the
denuded alveolar-capillary membrane, interstitial pro-
liferation of fibroblasts and myofibroblasts, or organizing
interstitial fibrosis [19, 20, 26].
Our strategy for mechanical ventilation of patients
with ARDS consisted of an initial low tidal volume of 6
to 8 mL/kg of predicted body weight for either volume-
controlled or pressure-controlled ventilation. Ventilatory
adequacy was monitored by arterial blood gas measure-
ments, with the ventilator settings changed as needed.
The PEEP levels were set according to a lower PEEP and
FiO2 strategy or at least 2 cm H2O above the lower inflec-
tion point derived from the P-V tool maneuvers of the ven-
tilator [27]. The plateau airway pressure was maintained
below 30 cm H2O combined the PEEP setting and low
tidal volume strategy. Pulse oximeter was used to monitor
oxygen saturation and the FiO2 was adjusted to maintain
SpO2 above 90 %. The plateau airway pressure was tried to
avoid raising above 30 cm H2O.
Clinical data collection
The following data were collected from the hospital
chart of each patient and analyzed: age, sex, underlying
diseases, acute physiology and chronic health evaluation
(APACHE) II score on the day of ICU admission [28],
sequential organ failure assessment (SOFA) score on the
day of ICU admission and the day of open lung biopsy
[29], lung injury score (LIS) [30], PaO2/FiO2 ratio, PEEP,
tidal volume, diagnostic procedures before open lung
biopsy (HRCT or BAL), complications related to surgery(i.e., postoperative air leak, pneumothorax, subcutaneous
emphysema, bleeding, and wound infection), patho-
logical diagnosis, hospital mortality, and therapeutic
alterations.
Postoperative therapeutic alterations indicated that the
results of open lung biopsy had led to the addition of
a new therapy, or the original therapy had been
stopped. Immunocompromised patients were defined
as follows: presence of HIV infection, recipient of
solid organ transplantation, recipient of hematopoietic stem
cell transplantation (HSCT), recipient of chemotherapy,
and recipient of long-term systemic corticosteroids for
more than 2 weeks.
Statistical analysis
All statistical analyses were performed using the SPSS stat-
istical package (SPSS for Windows, SPSS Inc., Chicago, IL,
USA). All values are reported as means ± SD. Categorical
data were tested using the chi-square test (or Fisher’s exact
test when the expected number of events was fewer than
five). Risk factors for hospital mortality were analyzed
by univariate analysis, and the variables statistically
significant (p <0.05) in the univariate analysis were
included in the multivariate analysis by applying multiple
logistic regression based on backward elimination of data.
The Hosmer-Lemeshow goodness-of-fit test was used for
calibration when evaluating the number of observed
and predicted deaths in risk groups for the entire range
of death probabilities. A p value <0.05 was considered
statistically significant.
Results
From 1 January 1999 to 31 January 2014, 1838 patients
were admitted to our ICUs with a diagnosis of ARDS, of
whom 101 had undergone open lung biopsy, and the
overall hospital mortality rate was 60.4 % (Fig. 1). Of the
1838 screened patients, 30 patients were excluded
because the symptom onset was more than 1 week ago
and had not met Berlin criteria. Among the 101 patients
who met the Berlin definition for ARDS, most patients
were classified as having moderate ARDS (n = 57, 56.5 %),
followed by severe ARDS (n = 27, 26.7 %), and mild ARDS
(n = 17, 16.8 %). The proportions of DAD were 76.5 %
(13/17) in mild, 56.1 % (32/57) in moderate and 44.4 %
(12/27) in severe ARDS and there were no significant
differences among these three groups (p = 0.113). According
to the severity on the biopsy day, the proportions of DAD
were 72 % (13/18) in mild, 56.9 % (33/58) in moderate and
44 % (11/25) in severe ARDS and there were no significant
differences among these three groups (p = 0.113). Figure 2
shows the pathological findings of diffuse alveolar damage
in the acute phase and organizing phase.
Baseline characteristics of these patients are shown
in Table 1. There were more male patients with ARDS
Fig. 1 Flow chart of study patients. ARDS Acute respiratory distress syndrome, MV mechanical ventilation, OLB open lung biopsy, DAD diffuse
alveolar damage
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six patients were had immunocompromised status,
including thirteen who had received chemotherapy
within a month before the onset of ARDS, six who were
recipients of HSCT, three who had HIV infection, three
who had received long-term systemic corticosteroids,
and one patient who had received a renal transplant.
The average PaO2/FiO2 ratios on the day of ARDS
diagnosis vs the day of biopsy were 142.4 ± 60.2 vs
148.7 ± 67.9, respectively.
Sixty-nine patients (68.3 %) had an HRCT of the chest
and 94 patients (93 %) underwent a flexible bronchoscopic
examination to identify the etiology of ARDS before open
lung biopsy. Among the 94 patients receiving broncho-
scopic examination, eight patients did not undergo BAL
due to severe hypoxemia during the procedure. Eighty
patients (79.2 %) underwent open-lung biopsy in the
operating room and 21 patients (21.8 %) received bedsideopen lung biopsy in the ICU. For open lung biopsy, VATS
was used in 57 patients (56.4 %), and thoracotomy was
performed in 44 patients (43.6 %). Thirty-eight patients
(37.6 %) received corticosteroids at the time of open lung
biopsy. Surgical complications were reported in 14
patients (13.9 %), but no complication resulted directly
in death. Eight patients had persistent air leak after
surgery, three patients had postoperative subcutaneous
emphysema, two patients had transient hypotension, and
one patient had a hemothorax.
All biopsy specimens exhibited abnormalities and
provided sufficient evidence for pathological diagnosis.
The pathological diagnoses of open lung biopsy are
shown in Table 2. DAD was diagnosed in 57 patients
(56.4 %); of these, there were 41 patients with DAD only
and 16 patients with DAD associated with another
condition. Of these 16 patients, 11 were classified as
having infection (4 patients with pneumocystis jiroveci
Fig. 2 Pathological findings of diffuse alveolar damage. a Diffuse
alveolar damage in the acute phase. The interstitium is edematous.
Hyaline membrane (arrow) is seen lining the alveolar ducts
(hematoxylin and eosin stain, ×100). b Diffuse alveolar damage in
the organizing phase. The interstitium is thickened with organizing
connective tissue. Prominent type 2 pneumocyte hyperplasia is seen
(hematoxylin and eosin stain, ×200)
Table 1 Baseline characteristics of patients with ARDS who had
open lung biopsy (n = 101)
Characteristic Value
Age 56.8 ± 16.8
Gender, number (male/female) 65/36
Immunocompromised, number 26 (26 %)
APACHE II score, ARDS diagnosis day 23.2 ± 5.5
SOFA score, ARDS diagnosis day 6.1 ± 3.2
PaO2/FiO2 (mm Hg), ARDS diagnosis day 142.4 ± 60.2
PEEP (cm H2O), ARDS diagnosis day 11.5 ± 2.1
SOFA score, biopsy day 7.0 ± 3.4
PaO2/FiO2 (mm Hg), biopsy day 148.7 ± 67.9
PEEP (cm H2O), biopsy day 11.8 ± 2.7
Tidal volume (mL), biopsy day 423.3 ± 99.6
Tidal volume (mL/predicted body weight) 8.3 ± 2.0
Duration from ARDS diagnosis to biopsy (days) 7.4 ± 7.1
Categories, ARDS diagnosis day, number (%) 101 (100 %)
Mild ARDS 17 (16.8 %)
Moderate ARDS 57 (56.5 %)
Severe ARDS 27 (26.7 %)
Categories, biopsy day, number (%) 101 (100 %)
Mild ARDS 18 (17.8 %)
Moderate ARDS 58 (57.4 %)
Severe ARDS 25 (24.8 %)
All values are expressed as number of patients (%) or mean ± SD.
Abbreviations: ARDS Acute respiratory distress syndrome, APACHE Acute
physiology and chronic health evaluation, SOFA Sequential organ failure
assessment, PaO2 Arterial partial pressure of oxygen, FiO2 Fraction of inspired
oxygen, PEEP Positive end-expiratory pressure
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Staphyloccus aureus, 1 with a viral infection and 1 with
mycobacterium tuberculosis), 2 as having an interstitial
lung pattern (both patients having organizing pneumonia)
and 3 were classified as having miscellaneous infection
(2 patients with metastatic adenocarcinoma and 1 with
vasculitis). Forty-four patients did not have DAD and
10 of these patients were classified as having infection
(1 patient with pneumocystis jiroveci pneumonia and
cytomegalovirus pneumonia, 2 with pneumocystis jiroveci
pneumonia, 2 with viral pneumonia, 2 with invasive fungal
infection, 2 with bacterial pneumonia and 1 with myco-
bacterium tuberculosis), 18 patients had interstitial lung
patterns (5 patients with usual interstitial pneumonia, 4
with organizing pneumonia, 2 with nonspecific interstitial
pneumonia, 1 with desquamative interstitial pneumonia, 1
with hypersensitive pneumonitis and 5 with unclassified
interstitial pneumonitis), and 16 patients were classified ashaving miscellaneous conditions (7 patients with fibrosis,
3 with leukemic infiltration, 2 with metastatic adenocar-
cinoma, 2 with vasculitis and 2 with lung edema). There
were 21 pneumonia patients including 11 patients
with DAD and 10 patients without DAD. The hospital
mortality rate was significantly higher in patients with
pneumonia and DAD (8/11) than in those with pneumonia
without DAD (2/10) (72.7 % vs 20 %, p = 0.03).
According to the results of open lung biopsy, 49
patients had alterations to their therapy (48.5 %). These
alterations included 16 patients who had steroid therapy
introduced, 7 patients whose antimicrobial agent was
changed, 1 patient who had chemotherapy introduced,
and 25 patients in whom certain medications were
discontinued, including withdrawal of antibiotics in viral
pneumonia and metastatic carcinoma, and withdrawal of
corticosteroids in bacterial pneumonia.
The hospital mortality rates were 64.7 % in mild ARDS,
61.4 % in moderate ARDS, and 55.6 % in severe ARDS
and there was no significant difference between the three
groups (p = 0.81). Table 3 shows the demographic and
clinical characteristics of survivors vs non-survivors
Table 3 Demographic and clinical characteristics of survivors







Age 54.5 ± 15.4 58.3 ± 17.6 0.274
Gender (male/female) 23/17 42/19 0.244
Immunocompromised (%) 32.5 21.3 0.208
APACHE II score, diagnosis day 23.4 ± 5.3 23.1 ± 5.7 0.838
SOFA score, diagnosis day 5.4 ± 2.6 6.6 ± 3.5 0.06
PaO2/FiO2 (mm Hg),
diagnosis day
136.5 ± 55.3 146.3 ± 63.4 0.427
SOFA score, biopsy day 5.2 ± 2.7 8.1 ± 3.4 <0.001*
PaO2/FiO2 (mm Hg), biopsy day 167.6 ± 69.3 136.3 ± 64.6 0.023*
PEEP (cm H2O), biopsy day 11.2 ± 2.7 12.2 ± 2.7 0.071
Tidal volume (mL), biopsy day 437.1 ± 86.0 413.4 ± 107.2 0.372
Duration from diagnosis to
biopsy (days)
7.1 ± 6.4 8.1 ± 7.1 0.232
Operative complication rate (%) 5 18 0.056




All values are expressed as number of patients (%) or mean ± SD; *p values
<0.05. Abbreviations: ARDS Acute respiratory distress syndrome, APACHE Acute
physiology and chronic health evaluation; SOFA Sequential organ failure
assessment, PaO2 Arterial partial pressure of oxygen, FiO2 Fraction of inspired
oxygen, PEEP Positive end-expiratory pressure, DAD Diffuse alveolar damage
Table 2 Pathological diagnosis of patients with ARDS who had
open lung biopsy (n = 101)
Pathological diagnosis Number (%)
DAD 57 (56 %)
DAD only 41
Infectious disease 11
Interstitial lung disease 2
Miscellaneous 3
Non-DAD 44 (44 %)
Infectious disease 11*
Interstitial lung disease 18
Miscellaneous 16
All values are expressed as number of patients (%) or mean ± SD. *One
pathology result included both pneumocystis jiroveci pneumonia and
cytomegalovirus pneumonia. Abbreviations: ARDS Acute respiratory distress
syndrome; DAD diffuse alveolar damage
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PaO2/FiO2 ratio on the day of open lung biopsy were
significantly different between survivors and non-survivors
(SOFA score 5.2 ± 2.7 vs 8.1 ± 3.4, p <0.001; PaO2/FiO2
167.6 ± 69.3 vs 136.3 ± 64.6, p = 0.023, respectively).
The finding of DAD on pathological examination was
significantly higher in non-survivors than survivors
(67.2 % vs 40 %, p = 0.007).
Univariate analysis was used to identify variables that
have prognostic value for hospital mortality, and multivari-
ate logistic regression analysis was used to identify variables
that did not have significant prognostic value (Table 4).
Identification of DAD on pathological examination (odds
ratio 3.554, 95 % CI 1.385, 9.120; p = 0.008) and SOFA
score on the biopsy day (odds ratio 1.424, 95 % CI 1.187,
1.707; p <0.001) were significantly and independently asso-
ciated with hospital mortality. Regression coefficients for
these variables were used to calculate a natural logarithm of
the odds (logit) of the probability of death (p) as follows:
logit pð Þ ¼ −2:522 þ 1:268  DADð Þ
þ 0:353  SOFA scoreð Þ:
Demographic and clinical characteristics of patients
with ARDS with DAD vs those without DAD are shown
in Table 5. There were no clinical characteristics that
could discriminate patients with DAD from those without
DAD before open lung biopsy. Patients with ARDS and a
pathologic diagnosis of DAD had a higher mortality rate
than those without DAD (71.9 % vs 45.5 %, p = 0.007).
Discussion
In our study, DAD was found in 56.4 % of patients who
had ARDS diagnosed using the Berlin definition and who
underwent open lung biopsy. The overall hospital mortalityrate was 60.4 %. DAD and SOFA scores obtained by patho-
logical examination on biopsy day were significantly associ-
ated with hospital mortality. Demographic and clinical
characteristics were not significantly different between
patients with and without DAD patients before open
lung biopsy.
The typical pathological finding of ARDS is DAD but
the correlation between clinical criteria for ARDS and
DAD is not well-understood [1, 9, 20, 21]. In an autopsy
series, of the 127 patients who met the AECC criteria for
ARDS, 66 % (84/127) were found to have DAD identified
on pathological examination [21]. In another study based
on autopsy data, DAD was documented in 43 % (35/82) of
patients who met the AECC criteria for ARDS [31].
Another autopsy study by Thille et al., identified DAD on
pathological examination in 45 % (159/356) of patients
who met the clinical criteria for ARDS according to the
Berlin definition at the time of death [23]. Furthermore,
DAD was more frequently identified (69 %) in those who
had severe ARDS for 72 hours or longer. In our open lung
biopsy data, DAD was noted in 56.4 % (57/101) of all
patients with ARDS and was more frequently found in
patients with mild ARDS (76.5 %). This difference in
frequency of DAD in patients with ARDS based on autopsy
vs open lung biopsy may be explained by the different dis-
tribution of ARDS among the patient groups. The majority
Table 4 Univariate and multivariate logistic regression analysis of clinical variables associated with hospital mortality
Parameter Beta coefficient Standard error Odds ratio (95 % CI) p value
Univariate logistic regression
Age 0.013 0.012 1.014 (0.989, 1.038) 0.272
Male gender −0.491 0.423 0.612 (0.267, 1.402) 0.246
Immunocompromised 0.575 0.460 1.778 (0.721, 4.381) 0.211
SOFA score, diagnosis day 0.130 0.071 1.139 (0.991, 1.307) 0.066
PaO2/FiO2, diagnosis day 0.003 0.003 1.003 (0.996, 1.010) 0.423
SOFA score, biopsy day 0.326 0.085 1.385 (1.173, 1.635) <0.001*
PaO2/FiO2, biopsy day −0.007 0.003 0.993 (0.987, 0.999) 0.03*
Treatment changes after biopsy −0.770 0.415 0.463 (0.205, 1.044) 0.063
DAD on biopsy 1.123 0.423 3.075 (1.343, 7.039) 0.008*
Multivariate logistic regression
DAD on biopsy 1.268 0.481 3.554 (1.385, 9.120) 0.008*
SOFA score, biopsy day 0.353 0.093 1.424 (1.187, 1.707) <0.001*
Constant −2.522 0.698 0.080 <0.001*
*p <0.05. In multivariate logistic regression, the Hosmer-Lemeshow test results (χ2 = 3.371, degrees of freedom = 8, p = 0.909). Abbreviations: SOFA Sequential
organ failure assessment, PaO2 Arterial partial pressure of oxygen, FiO2 fraction of inspired oxygen, DAD diffuse alveolar damage
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autopsy but had moderate ARDS in the present study based
on open lung biopsy.
The percentage of patients with ARDS who were
found to have DAD on open lung biopsy varies widely
among studies. Papazian et al. reported results of a
retrospective study of patients with ARDS who met
AECC criteria and who underwent open lung biopsy [14].
They found that 13.8 % (5/36) of patients had DAD. In
another study, Papazian and coworkers prospectively
studied 100 patients with ARDS who fulfilled AECCTable 5 Demographic and clinical characteristics of patients with AR
Characteristics DAD (n = 57
Age 56.6 ± 1
Gender (male/female) 36/21
Immunocompromised (%) 28.1
APACHE II score, diagnosis day 22.6 ± 6
SOFA score, diagnosis day 6.3 ± 3
PaO2/FiO2 (mm Hg), diagnosis day 148.6 ± 6
SOFA score, biopsy day 7.3 ± 3
PaO2/FiO2 (mm Hg), biopsy day 158.5 ± 7
PEEP (cm H2O), biopsy day 12.0 ± 3
Tidal volume (mL), biopsy day 422.3 ± 9
Duration from diagnosis to biopsy (days) 7.6 ± 6
Operative complication rate (%) 10.5
Treatment changes after biopsy (%) 43.9
Hospital mortality (%) 71.9
All values are expressed as number of patients (%) or mean ± SD; *p values <0.05. A
syndrome, APACHE Acute physiology and chronic health evaluation; SOFA Sequenti
Fraction of inspired oxygen, PEEP Positive end-expiratory pressurecriteria and who underwent open lung biopsy; 13 % were
identified to have DAD on pathological examination [17].
In Patel’s study of open lung biopsy in patients with
ARDS, 40 % (23/57) of patients had DAD on pathologic
examination [15]. In our previous study, DAD was found
in 29.3 % (12/41) of patients with early-stage ARDS, who
were receiving open lung biopsy [16]. A recent study
in non-resolving ARDS showed the DAD was found
in 57.8 % (48/83) patients who had open lung biopsy
[32]. In the present study of open lung biopsy, DAD
was noted in 56.4 % (57/101) of patients with ARDSDS with DAD versus patients without DAD
) No DAD (n = 44) p value
7.5 57.1 ± 16.1 0.876
29/15 0.775
22.7 0.543
.1 23.7 ± 5.1 0.506
.7 5.9 ± 2.5 0.492
2.0 134.1 ± 57.3 0.234
.9 6.6 ± 2.7 0.326
2.5 136.0 ± 59.9 0.099
.0 11.5 ± 2.3 0.423
5.4 422.4 ± 108.5 0.995




bbreviations: DAD Diffuse alveolar damage, ARDS Acute respiratory distress
al organ failure assessment, PaO2 Arterial partial pressure of oxygen, FiO2
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percentages of DAD in patients with ARDS (from 13.5 % to
57.84 %) based on open lung biopsy may be attributable to
the different indications, definition and timing for open
lung biopsy in each of the studies.
In this study, we demonstrated that a DAD identified on
pathological examination correlated with increased mor-
tality in patients with ARDS identified using the Berlin
definition. In a study by Parambil et al., the hospital mor-
tality rate in patients with DAD was 58 % in patients with
ARDS compared to 17 % in patients without ARDS [31].
In a study of patients with ARDS (Papazian et al.), the
factors predicting survival included female gender, organ
system failure score on the day of biopsy, and biopsy
result leading to the addition of a new drug [17]. Another
open lung biopsy study was performed in mechanically
ventilated patients with undiagnosed diffuse pulmonary
infiltrates to determine factors independently associated
with survival [33]. They found that the Charlson age-
comorbidity index score, number of organ dysfunctions,
and the PaO2/FiO2 ratio on the day of biopsy were associ-
ated with survival. A study in patients with non-resolving
ARDS, who had open lung biopsy showed that the ICU
mortality rate was higher in patients with DAD than in
those without DAD (67 % vs 57 %), but this was not
significantly different [32]. The present study demon-
strated that patients with DAD had significantly increased
hospital mortality compared to those without DAD
(71.9 % vs 45.5 %, p = 0.007). The poor survival outcome
in patients with DAD may imply more severe lung injury
in patients with ARDS with vs without DAD. However, no
clinical characteristic differentiated between patients with
and without DAD before open lung biopsy (Table 5). Our
study highlights the heterogeneity of patients with ARDS
and discrepancy between the clinical and pathological
definitions of ARDS. A distinct phenotype of patients
with ARDS characterized by DAD needs to be further
addressed due to it having worse outcomes.
A meta-analysis of open lung biopsy in patients with
ARDS summarized that the surgical complication rate was
22 %; the most common complication was prolonged air
leak, but mortality resulting from surgery was infrequent
[34]. Meanwhile, open lung biopsy could offer a specific
diagnosis in 84 % of patients and altered management
in 73 % of patients. Our study revealed that the surgical
complication rate was 13.9 % and management alteration
rate was 48.5 % in these selected patients with ARDS. The
survival advantage of open lung biopsy in ARDS is still not
approved due to lack of a randomized controlled trial. Prac-
tically, it is important to assess the balance between the
potential risk of surgical complications and diagnosis or
treatment benefit in deciding to perform open lung biopsy.
There were several limitations of our study. First, it is
a retrospective study in one referred medical center,which may limit the generalization to all other ICUs.
Given the patients included retrospectively from the
charts, some patients with ARDS may have been missed.
In addition, the ICD-9 diagnosis code 518.82 excludes
ARDS associated with trauma and surgery and includes
all type of hypoxemic acute respiratory failure. Some
patients with trauma-associated or surgery-associated
ARDS may be missed in our study. However, it is one of
the largest studies in patients with ARDS having open
lung biopsy. Second, the decision to perform open lung
biopsy was highly selective and only 5.5 % of patients
with ARDS were referred for biopsy in this study. The
results, therefore, are unlikely to be representative of all
patients with ARDS. However, the potential for selection
bias for patients with ARDS may be lower with open
lung biopsy than with autopsy as the patients are alive.
Third, only 85 % of patients had BAL before open lung
biopsy. Some specific diagnoses may have been missed
because their recognition depended on the availability of
laboratory facilities. Fourth, the lung specimens were
assessed by one pulmonary pathologist only and so the
possibility of individual interpretation bias should be
considered. Finally, there was no standard treatment
for patients with some specific diagnoses, such as
interstitial lung disease, after the biopsy result became
available. Specific treatments such as corticosteroid
therapy might have influenced the survival outcome in
these patients.
Conclusions
This retrospective study demonstrated that 56.4 % of
selected patients with ARDS based on the Berlin definition
and who underwent open lung biopsy were identified as
having DAD. As a result of the moderate agreement
between clinical and pathological diagnosis of ARDS, open
lung biopsy may be considered in some patients to
exclude or to clarify the diagnosis. According to the
results of pathological examination, patients with
DAD had poorer outcomes than patients without
DAD. However, there was no clinical characteristic
that discriminated between patients with and without
DAD before open lung biopsy. In future studies of
ARDS, the clinical therapeutic trial may focus on this
subgroup owing to the high mortality among these patients.
In addition to open lung biopsy, some non-invasive
modalities such as serum biomarkers and HRCT may be
used to identify this distinct type of patient with ARDS.
Key messages
 This retrospective study demonstrated that 56.4 %
of selected patients with ARDS based on Berlin
definition, and who underwent open lung biopsy
were found to have DAD.
Kao et al. Critical Care  (2015) 19:228 Page 9 of 10 Patients with DAD identified on pathological
examination had significantly higher hospital
mortality than patients without DAD, and there was
no clinical characteristic that differentiated between
patients with and without DAD before open lung
biopsy.
 In future studies, the clinical therapeutic trial may
focus on patients with ARDS and DAD and
investigate some non-invasive modalities to identify
this subgroup of patients with ARDS.
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